drugset / Trial / NCT02422940

Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.

NCT02422940

Phase 3 Terminated 294 enrolled Acorda Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is an extension study to evaluate the long-term safety, tolerability, and efficacy of two dose strengths of dalfampridine-ER.

Timeline

Start
2015-04
Primary completion
2017-01
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dalfampridine Small molecule 7.5 mg Oral
Comparator Dalfampridine Small molecule 10 mg Oral

Indications